Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

November 25, 2013

Company Founded by Five World Leaders in Genome Editing; Secures $43 Million Series A Financing Led by Flagship Ventures, Polaris Partners and Third Rock Ventures

Three VCs Pour $43M Into Editas to “Edit” Out Genetic Disorders

Three VCs Pour $43M Into Editas to “Edit” Out Genetic Disorders

November 25, 2013

Gene therapy, make way for gene “editing.”

Today, three of Boston’s biotech startup creators—Polaris Partners, Third Rock Ventures, and Flagship Ventures, have banded together to create a new, Cambridge, MA-based startup called Editas Medicine.

Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

November 25, 2013

If Approved, Avedro Could Be Entitled to Seven Years Market Exclusivity

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration (FDA) stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date (PDUFA) at March 15th, 2014.

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

November 21, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Stéphane Bancel, President and Founding Chief Executive Officer (CEO) of Moderna Therapeutics, and Senior Partner at Flagship Ventures, has joined its Board of Directors.

Flagship VentureLabs™ Introduces Seres Health - Early Leader in the Development of Novel Therapeutics to Treat Diseases of the Human Microbiome

Flagship VentureLabs™ Introduces Seres Health - Early Leader in the Development of Novel Therapeutics to Treat Diseases of the Human Microbiome

November 21, 2013

Company Appoints Dr. Roger J. Pomerantz as Chairman

Flagship Takes a Stab at Microbiome Therapy With Seres Health

Flagship Takes a Stab at Microbiome Therapy With Seres Health

November 21, 2013

By Luke Timmerman of Xconomy

We live every day with trillions of bacterial neighbors that do all sorts of mysterious things in our guts, good and bad. The broadening scientific understanding of the “microbiome”, powered by the modern tools of genomic analysis, has been in the news for a while.

Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs

Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs

November 20, 2013

By Luke Timmerman of Xconomy

Moderna Therapeutics doesn’t need cash to keep the doors open, like many biotech startups. It just went out and raised a ton of dough, anyway.

The Cambridge, MA-based biotech startup, which is attempting to make injectable messenger RNA molecules that trigger production of protein drugs in the body, has raised a whopping $110 million in new equity financing.

Moderna Therapeutics Announces New Equity Financing, Raising $110M to Develop messenger RNA Therapeutics™

Moderna Therapeutics Announces New Equity Financing, Raising $110M to Develop messenger RNA Therapeutics™

November 20, 2013

Latest round boosts capital reserves to advance numerous drug candidates into clinical testing directly and through strategic partners

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

November 19, 2013

WALTHAM, Mass., Nov 19, 2013 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]

Tetraphase Reports Third-Quarter 2013 Financial Results

Tetraphase Reports Third-Quarter 2013 Financial Results

November 14, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended September 30, 2013.